Azithromycin + Rifabutin/rifampin
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Mycobacterium Avium Complex
Conditions
Mycobacterium Avium Complex
Trial Timeline
Dec 1, 1994 → May 18, 2017
NCT ID
NCT00598962About Azithromycin + Rifabutin/rifampin
Azithromycin + Rifabutin/rifampin is a approved stage product being developed by Pfizer for Mycobacterium Avium Complex. The current trial status is completed. This product is registered under clinical trial identifier NCT00598962. Target conditions include Mycobacterium Avium Complex.
What happened to similar drugs?
2 of 7 similar drugs in Mycobacterium Avium Complex were approved
Approved (2) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00598962 | Approved | Completed |
Competing Products
20 competing products in Mycobacterium Avium Complex